Alto Neuroscience (ANRO) Projected to Post Earnings on Wednesday

Key Points

• Alto Neuroscience is expected to report Q1 2026 results before the market opens on May 13, 2026, with analysts projecting EPS of ($0.56); the company will host an earnings call on May 14 at 9:30 AM ET, and last quarter it reported ($0.45) EPS, beating estimates by $0.11.
• The stock trades near $25.46 with a 52‑week range of $2.12–$28.44 and a market capitalization of about $813 million, while the company shows very high liquidity (current and quick ratios ~15.7).
• Wall Street consensus is a Moderate Buy (seven Buys, one Hold, one Sell) with a $35.13 average price target, even as analysts expect roughly −$2 EPS for the current fiscal year and −$3 EPS for the next.

Alto Neuroscience (NYSE:ANRO - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. On average, analysts expect Alto Neuroscience to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Alto Neuroscience Stock Performance

Alto Neuroscience stock opened at $25.46 on Wednesday. Alto Neuroscience has a 52 week low of $2.12 and a 52 week high of $28.44. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. The stock has a market cap of $813.29 million, a P/E ratio of -11.68 and a beta of 1.62. The stock has a 50 day moving average of $22.56 and a 200-day moving average of $17.75.

Institutional Trading of Alto Neuroscience

Several hedge funds have recently added to or reduced their stakes in ANRO. AQR Capital Management LLC bought a new position in shares of Alto Neuroscience in the 1st quarter worth $52,000. Invesco Ltd. bought a new stake in shares of Alto Neuroscience in the first quarter valued at about $67,000. Bridgeway Capital Management LLC grew its stake in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company's stock worth $119,000 after acquiring an additional 25,000 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $198,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Alto Neuroscience in the fourth quarter valued at approximately $221,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ANRO. JonesTrading dropped their price target on Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating on the stock in a research report on Thursday, April 2nd. BTIG Research boosted their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Wedbush cut their price target on Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating on the stock in a report on Thursday, April 2nd. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Alto Neuroscience in a research report on Thursday, April 2nd. Finally, Bank of America began coverage on Alto Neuroscience in a research note on Tuesday. They issued a "buy" rating and a $35.00 price target for the company. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $35.13.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.